Formula I Compound E-Selectin Inhibition AML Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and neutropenia are limited, with few effective options for relapsed AML and MDS, and existing therapies for mucositis are largely palliative, leading to significant morbidity and mortality.
Innovation Solution
Administration of a compound of Formula (I), which can be given as a fixed or weight-based daily dose, either as a single dose or divided over the day, intravenously or subcutaneously, in combination with chemotherapy and/or radiotherapy, to inhibit E-selectin-mediated pathways and reduce chemotherapy-induced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy and radiotherapy are administered to treat AML and MDS, then cancer cell killing effectiveness is improved, but chemotherapy-induced toxicity including neutropenia and mucositis increases
Solution Approach 1:
The compound of Formula (I) acts as an intermediary agent that blocks E-selectin-mediated adhesion pathways. This interference prevents leukemic cells from adhering to endothelial cells and bone marrow stroma, thereby enhancing chemotherapy effectiveness while simultaneously reducing toxicity by preventing cell sequestration and tissue damage
Solution Approach 2:
The invention changes the biological parameter of E-selectin expression and activity on endothelial cells. By modulating this adhesion molecule's function, the treatment alters the interaction between leukemic cells and the vascular system, reducing both tumor protection and toxic side effects
2Object-affected harmful factors
If E-selectin-mediated pathways are inhibited to reduce toxicity, then chemotherapy-induced toxicity is reduced, but cancer cell killing effectiveness may be compromised
Solution Approach 1:
The compound of Formula (I) selectively blocks the E-selectin adhesion pathway without interfering with chemotherapy's direct cytotoxic mechanisms. This targeted interference reduces toxicity by preventing protective adhesion while leaving cancer cell killing pathways intact
Solution Approach 2:
The invention extracts and specifically targets the harmful E-selectin-mediated adhesion function from the overall cancer treatment process. By isolating and blocking this specific pathological pathway, the treatment removes the protective mechanism that shields leukemic cells from chemotherapy while preserving essential anti-cancer effects
3Reliability
If stem cell transplantation is performed to treat relapsed AML, then potential cure is achieved, but treatment availability and patient survival are limited due to donor matching requirements
Solution Approach 1:
The invention segments the treatment approach from the restrictive stem cell transplantation model. By developing a pharmacological intervention that can be administered independently of donor availability, the treatment creates a standalone therapeutic option that addresses relapsed AML without requiring complex matching procedures
Solution Approach 2:
The compound of Formula (I) serves as a universal treatment option for relapsed AML across diverse patient populations. Unlike stem cell transplantation which requires specific donor-recipient compatibility, this pharmacological approach can be applied universally regardless of donor availability or matching status
Data Source
AI summary
Methods for treating or inhibiting cancer and/or one or more related conditions by administering to a subject in need thereof an effective amount of a compound of Formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing. For example, methods for treating AML, MDS, neutropenia, and/or mucositis comprising administering a pharmaceutical composition comprising a compound of Formula (I) are described.